Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice
Open Access
- 24 December 2008
- journal article
- research article
- Published by Elsevier
- Vol. 19 (3) , 639-643
- https://doi.org/10.1016/j.bmcl.2008.12.059
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- CB2 receptors as new therapeutic targets for liver diseasesBritish Journal of Pharmacology, 2008
- Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: EfficacyThe American Journal of Cardiology, 2007
- The endocannabinoid system and gut–brain signallingCurrent Opinion in Pharmacology, 2007
- Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole – LH 21Neuropharmacology, 2006
- How many sites of action for endocannabinoids to control energy metabolism?International Journal of Obesity, 2006
- Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by CholecystokininJournal of Neuroscience, 2004
- Endogenous cannabinoid system as a modulator of food intakeInternational Journal of Obesity, 2003
- Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexusJournal of Comparative Neurology, 2002
- Reversal of Δ9-THC hyperphagia by SR141716 and naloxone but not dexfenfluraminePharmacology Biochemistry and Behavior, 2002
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorPublished by Wiley ,2001